Articles by Brandon Twyford
Final TALAPRO-2 results show talazoparib + enzalutamide significantly improves survival in patients with HRR-deficient mCRPC.
The study found no PFS benefit for tivozanib plus nivolumab in RCC post-ICI, but tivozanib maintained quality of life.
Neoadjuvant durvalumab plus chemotherapy shows promising pathologic response rates, favorable safety profile in UTUC.
EV+P continues to show superior efficacy and durable responses in previously untreated locally advanced or metastatic UC.
The study found promising results with lenvatinib + belzutifan for patients with previously treated RCC.
Radiotherapy may reduce distant metastasis risk in high-risk prostate cancer compared to surgery, according to new study.
The FDA's Fast Track Designation enables expedited development of 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging.
Durvalumab was granted FDA Priority Review for MIBC, after showing significant survival benefits in the NIAGARA trial.
TARA-002 shows promising efficacy, safety in the ADVANCED-2 trial for NMIBC, with high response rates across BCG exposures.
Ferring has advanced three clinical trials assessing nadofaragene as a monotherapy and combination therapy for NMIBC.
Several posters and a late-breaking abstract will highlight data on cretostimogene grenadenorepvec for bladder cancer.
The real-world analysis of olaparib for HRRm+ CRPC showed that earlier treatment resulted in higher PFS and OS.
The study examined the prognostic value of ctDNA as a biomarker in patients with muscle-invasive bladder cancer.
ANKTIVA plus BCG shows a 71% CR rate and up to 54 months of durable response in patients with BCG-unresponsive NMIBC-CIS.
Clarity's head-to-head trial evaluates diagnostic performance of 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11.
The COBRA study on SAR-bisPSMA for prostate cancer detection will be presented at the EANM 2024 Congress.
The TiNivo-2 trial found that a tivozanib-nivolumab combination therapy did not improve outcomes over tivozanib alone.
ctDNA testing may help identify patients with bladder cancer who would benefit from early post-cystectomy immunotherapy.
Disitamab vedotin plus pembrolizumab shows promising efficacy, manageable safety in HER2+ aUC, with a 61.1% response rate.
AUC3 seeks to reshape the landscape of GU cancer management through interdisciplinary dialogue and consensus building.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.